“Yiqi Huayu, Wenyang Lishui” Prescription (YHWLP) Improves the Symptoms of Chronic Obstructive Pulmonary Disease-Induced Chronic Pulmonary Heart Disease by Inhibiting the RhoA/ROCK Signaling Pathway

• Published in: Evidence-based complementary and alternative medicine Vol. 2021; pp. 6636426 - 8
• Main Authors: Huang, Hui, Shan, Kuizhong, Cai, Min, Chen, Hong, Wu, Fengmei, Zhao, Xiaoyan, Zhuang, Huawei, Li, Hong, Shi, Suofang
• Format: Journal Article
• Language: English
• Published: United States Hindawi 2021; Hindawi Limited
• Subjects: Anticoagulants; Blood pressure; Cardiovascular disease; Chinese medicine; Chronic obstructive pulmonary disease; Cor pulmonale; Coronary artery disease; Cyanosis; Edema; Fibrinogen; Heart diseases; Heart failure; Hypertension; Lung diseases; Mortality; Myosin; Obstructive lung disease; Peripheral blood; Proteins; Prothrombin; Pulmonary arteries; Rho-associated kinase; RhoA protein; Signal transduction; Software; Thromboplastin; Veins & arteries; United States > US; China
• ISSN: 1741-427X; 1741-4288
• DOI: 10.1155/2021/6636426

Background. Chronic pulmonary heart disease (CPHD) is a common type of heart disease. In China, chronic obstructive pulmonary disease (COPD) is one of the main causes of CPHD. At present, there is no specific therapy for COPD-induced CPHD, so it is of great importance to identify a new therapy for CPHD. Objective. The purpose of this study was to explore the effects of “Yiqi Huayu, Wenyang Lishui” prescription (YHWLP) on CPHD symptoms. Methods. Eighty patients with COPD-induced CPHD were randomly divided into the control group and the YHWLP group, both involving treatment for 3 months. Both groups were treated with Western medicine, and the YHWLP group was also treated with YHWLP. The changes (relative to baseline) in the symptoms, pulmonary arterial pressure, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen (Fbg), D-dimer (D-D), and ratio of phosphorylated (p)-myosin-binding subunit (MBS)/total (t)-MBS in peripheral blood (which indirectly indicates the activation/inhibition of RhoA/ROCK signaling) were compared between the two groups. Results. YHWLP plus Western medicine was superior to Western medicine alone at reducing symptoms, pulmonary arterial pressure, PT, aPTT, Fbg, D-D, and p-MBS/t-MBS. Conclusion. YHWLP can relieve CPHD by inhibiting the RhoA/ROCK signaling pathway, which means YHWLP is a potential treatment for CPHD.